Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
protein degradation
Biotech
Novartis pays $150M for Arvinas' prostate tumor protein degrader
The deal, which is worth up to $1.01 billion in milestones, will give Novartis global rights to a degrader of wild-type and mutant androgen receptor.
Nick Paul Taylor
Apr 11, 2024 8:04am
Gilead dives deeper into Nurix protein degrader collab
Apr 2, 2024 9:10am
Merck KGaA paying $16M to join C4's protein degrader hunt
Mar 4, 2024 10:18am
Firefly Bio assembles with $94M and an ADC dream team
Feb 15, 2024 8:11am
Amphista protein degraders effective against cancer in animals
Jan 24, 2024 4:30am
Roche pays $50M to Monte Rosa in latest molecular glue deal
Oct 17, 2023 8:25am